Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy
- Collaboration to combine Aimmune’s therapy with Dupixent
- Phase 2 clinical trial, funded by Regeneron, to start in 2018
Peanuts are offered for sale at Eastern Market on Capitol Hill in Washington, DC, on June 27, 2008.
Photographer: Saul Loeb/AFP/Getty ImagesThis article is for subscribers only.
Aimmune Therapeutics Inc. is teaming with Regeneron Pharmaceuticals Inc. in hopes of developing a cure for peanut allergies.
Aimmune, based in Brisbane, California, specializes in food allergy treatments and has been developing a desensitizing therapy, AR101, to protect peanut allergy sufferers against reactions from accidental exposures. By combining AR101 with Regeneron’s inflammation-inhibiting drug Dupixent, the companies are seeking to increase protection enough so patients stop reacting to peanuts even after treatment ends.